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CONCLUSIONS: The translation evidence tracking tool is a unique device enabling
researchers to submit a consistent and comprehensive translation dossier for FDA
review.
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FINAL REPORTS FOR TRANSLATION AND LINGUISTIC VALIDATION OF
CLINICAL OUTCOME ASSESSMENTS
Zarzar K1, Chulis C2, Simon M3
1TransPerfect, Research Triangle Park, NC, USA, 2TransPerfect, New York, NY, USA,
3TransPerfect, Paris, France
OBJECTIVES:As the use of existing translated clinical outcome assessments (COAs)
across studies is common and continues to increase, appropriate documentation
of the translation and linguistic validation processes utilized to create target lan-
guage versions is essential.METHODS:A review of the contents of final reports and
certifications for previously completed COA translations was conducted. Addi-
tional discussions with sponsors and CROs regarding final reports, and the preva-
lence of final report deliveries from linguistic validation providers across the in-
dustry were completed. RESULTS: Final reports for linguistic validation are not
provided consistently across the industry. While some companies provide a final
report for every project, upon further discussion with sponsors within the industry
it was revealed that some companies do not automatically generate reports or
provide them to sponsors upon completion of the linguistic validation process.
Based upon regulatory expectations for review of translated COAs, it is recom-
mended to utilize a final report which summarizes the overall linguistic validation
project. This report should document the process used in detail, the reasoning for
linguistic decisions at each stage, evidence of cognitive interviewing, cognitive
interviewing population, demographic information of the respondents, a summary
of the findings, the final formatted version of the questionnaire, and the relevant
certification.CONCLUSIONS: Final reports for COA language versions provide valu-
able information needed to make critical decisions regarding the use of existing
translations. Linguistic validation reports should be structured as a complete pack-
age addressing each item regulatory authorities require for review of translations,
so the sponsor may easily include this in their submission packages. Final reports
should be provided for every COA language version to document the translation
and linguistic validation process completed.
PRM130
TRANSLATABILITY OF RESPONSE SETS USED IN PATIENT REPORTED
OUTCOMES AND BEST PRACTICES FOR DEVELOPMENT
Gawlicki MC1, McKown S2, Talbert M2, Brandt BA1
1Corporate Translations, Inc., East Hartford, CT, USA, 2Corporate Translations, Inc., Chicago, IL,
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OBJECTIVES: To determine the best response sets for use in Patient Reported Outcomes
(PRO) instruments intended for translation and subsequent data collection in multina-
tional clinical trials, and to make recommendations for response options to avoid. As
sound response sets are essential for data collection, a high degree of translatability is
vital.METHODS: Twelve response sets from previously translated PRO instruments
were analyzed. Additionally, linguists provided their feedback on translatability of
the response sets. Observed response sets included measures of patient treatment
satisfaction, improvement, discomfort level, frequency of symptoms or adverse
affects and agreement level with statements about treatment or condition.
RESULTS:A response set constructed of “Strongly agree, agree, uncertain, disagree,
strongly disagree” was conceptually equivalent to the source in 94% of observed
back-translations. In comparison, response options including the phrase “. . .of the
time” were conceptually equivalent in 42% of back-translations. The concept of
“fair” was conceptually equivalent in 64% of back-translations and was found to
have negative interpretations in some languages, such as “Weniger gut” (“not so
good”) in German, and positive in others, such as “Elfogadható” (“acceptable”) in
Hungarian. Some response options within response sets may be indistinguishable
when translated, such as “a little bit” and “somewhat.” Furthermore, “bit” is a
non-existent concept in languages other than English. CONCLUSIONS: Response
sets in PROs should achieve equivalence across languages, with no overlap between op-
tions. The aforementioned agreement set is easily localized, and is thus recommended.
Use of verbose terminology and concepts which are non-existent in other languages
should also be avoided. A translatability assessment of response sets is recommended
during instrument development. Where appropriate the use of numerical rating scales or
visual analogue scales is recommended. Such response sets avoid concept overlap, and
numerical results avoid translatability issues.
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HOW MIGHT EXPERIENCE-BASED UTILITY MEASURES INFLUENCE
REIMBURSEMENT DECISIONS?
Marsh K, Browne C
United BioSource Corporation, London, UK
OBJECTIVES: The measurement of the ‘quality’ part of the QALY used to assess
health interventions is conventionally based upon the general publics’ preferences
for different health states. Research from behavioural economics tells us that the
elicitation of preferences to inform this analysis introduces a number of biases into
the estimation of the utility generated by technologies. In response to this, various
authors have considered the theoretical possibility of replacing the preference-
based approaches with experience-based estimates of health related utility gains.
This paper compares the ICERs for a range of interventions estimated based on
both preference-based and experience-based valuation techniques. METHODS:
Tariffs associated with changes in health states were extracted from published
data. Tariffs based on four methods were identified: TTO, standard gamble, life
satisfaction, and day affect. These data were combined with estimates of the cost
and effect of a range of interventions to model the impact on ICERs of these alter-
native tariffs, how this varied with intervention type and tariff method, and the
challenges of adopting alternative tariffs. RESULTS: Experience-based utility mea-
sures generate lower ICERs for interventions that generated improvements in the
social and mental dimensions of health outcomes, and higher ICERs for those that
target the pain dimensions of health outcomes. This trend is not, however, repli-
cated across different experience-based utility measures. CONCLUSIONS: Experi-
ence-based utility represents an alternative to the preference-based utility mea-
sures conventionally employed within health economics. If optimal use is to be
made of health care budgets, further work is required to understand why different
utility measures produce different ICERs, and further debate is required to inform
the appropriate basis for reimbursement decisions.
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USING CLINICAL OUTCOME ASSESSMENTS AND ECONOMIC DATA TO
FACILITATE PATIENT ACCESS IN RHEUMATOID ARTHRITIS
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OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease, affecting
over 2.9 million adults in Europe. A challenge for new RA therapies is demonstrat-
ing added value not only in efficacy and tolerability but also in terms of overall
benefit for patients, carers, health care systems and society. The aims of this study
were to document current unmet needs in RA in terms of patient-reported and
economic burden and how such concepts may be assessed to capture the value of
RA treatments. METHODS: Articles were identified via searches in MEDLINE, EM-
BASE, EconLit, HEED, CRD databases and PSYCINFO using pre-defined search terms
and limits. PRO measures were identified via the reviewed literature and the Pa-
tient-Reported Outcome and Quality of Life Database (PROQOLID) and were as-
sessed in context of FDA guidelines. RESULTS: The literature search revealed 2,517
abstracts of which 123 articles were reviewed in full. RA symptoms significantly
impact patient’s physical functioning, daily activities, and ability to work. Financial
stability of patients and caregivers is affected and direct and indirect costs are
incurred by health care systems. A conceptual model summarising patient-re-
ported and economic burden of RA was developed to identify key measurement
concepts which can demonstrate efficacy, tolerability, and wider impact of RA
treatments. Relevant endpoint measures were identified; beyond traditional symp-
tom reports the assessment of health-related quality of life, sleep, fatigue, daily
activities, resource use and work productivity can provide data for regulatory, re-
imbursement, patient, and physician decision making. CONCLUSIONS: A patient-
focused approach is increasingly advocated for underpinning individual and soci-
etal health care decisions. PRO measures, therefore, are essential for monitoring
treatment outcomes among RA patients both in clinical trials and clinical practice.
Where adequate instruments are included in clinical trials there exists opportunity
to demonstrate the overall efficacy, tolerability, and value of a treatment to key
stakeholders including regulatory and HTA bodies.
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OBJECTIVES: When developing a new PRO for use in multinational studies it is
recommended that a translatability assurance step is conducted before finalization
and its subsequent translation and linguistic validation. A review of translatability
and subsequent adaptation can reduce the chances of encountering difficulties
related to concepts, idiomatic expressions, response scales, or syntax once trans-
lation has started. This step helps identify potential issues and develop solutions
that side-step potential problems in the later translation process. The aim of this
study was to assess the nature of issues that translatability highlights. METHODS:
Translatability is assessed by native speakers representing several language
groups (e.g. Europe, Africa, Asia, and Latin America). The linguists are asked to
identify possible grammatical, lexical and cultural issues. Their recommendations
are compiled and discussed with the developer of the measure, which is then
adapted in accordance with these findings. The results of translatability checks
were reviewed to find common issues that the process illuminates. RESULTS:
Changes made to a PRO as a direct result of a translatability step can be varied but
all work towards clarity of concepts and expression. Common changes are: 1) Com-
plex sentences are segmented for clarity; 2) Ambiguity is removed; 3) Constructs
common in English but not in other languages are changed; 4) Colloquialisms are
simplified; 5) Elaborations are added to clarify concepts; and 6) Unnecessary noun
repetition is removed. CONCLUSIONS: The translatability assurance step can in-
crease cross-cultural equivalence between original and translated documents, and
tackle potential translation difficulties uniformly before translation begins. It is
recommended as a step in all PRO development projects.
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REGRESSION METHODS FOR HEALTH-RELATED QUALITY OF LIFE DATA IN
LONGITUDINAL SETTINGS: ARE MORE ADVANCED TECHNIQUES REALLY
PERFORMING BETTER?
Hunger M, Döring A, Holle R
Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH),
Neuherberg, Germany
OBJECTIVES: The statistical analysis of health utilities and health-related quality
of life (HRQL) scores poses various challenges due to the distributional properties
such data commonly exhibit. These include skewness and heteroscedasticity
A484 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
caused by the bounded scale. Various analytical approaches have recently been
proposed for use in cross-sectional studies, however, less attention is paid to lon-
gitudinal designs. We examined the use of beta regression models to analyze HRQL
data over time using two empirical examples. METHODS: The HRQL measures
employed in our empirical examples were the generic SF-6D and the disease-spe-
cific Stroke Impact Scale (SIS). Data came from the German KORA cohort study and
from a clinical setting, respectively. We fitted mixed and marginal beta models and
explain the conceptual difference between these two model classes, namely the
population-averaged and the subject-specific perspective. We compared overall fit
and predictive accuracy of the models to the commonly used linear mixed model
(LMM). RESULTS: The SF-6D data were highly skewed to the left and the SIS data
exhibited a pronounced ceiling effect. In both examples, the beta distribution fitted
the data better than the normal distribution. Beta regression accounted for the fact
that predicted values must fall into the bounded support of the scales and overall
fit measures suggested that the mixed beta model was superior to the LMM (AIC:
2723 vs.2441 and904.1 vs.376.4). However, mixed beta regression underes-
timated the mean at the upper part of the distribution. Adjusted group mean scores
from the marginal beta model were nearly identical to those derived from the LMM.
CONCLUSIONS: Longitudinal beta regression models are potential candidates to
analyze HRQL over time since they account for the specific characteristics such
data typically have. However, our results show that in practice, estimates may only
differ slightly from those of commonly used methods.
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VALIDITY, RELIABILITY AND RESPONSIVENESS OF THE SPANISH MINNESOTA
LIVING WITH HEART FAILURE QUESTIONNAIRE
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OBJECTIVES: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is
one of the most used specific instruments for measuring quality of life in patients
with heart failure. It comprises 21 items conforming a total score, as well as two
domains: the physical and the emotional. The aim of this study was to evaluate the
reliability, validity, and responsiveness of the Spanish MLHFQ.METHODS: Patients
completed the MLHFQ and the SF-12 during their hospitalization for heart failure
(n1175), and 6 months after discharge (n473). Reliability was assessed by Cron-
bach’s alpha coefficient. Confirmatory factor analysis (CFA) for categorical vari-
ables was used to study construct validity. Convergent validity was assessed by
correlations between MLHFQ and SF-12 scales. To study known-groups validity,
MLHFQ at 6 months were compared according to readmission. Responsiveness was
evaluated by effect sizes and according to patients classified as improved, equal, or
worsened than at baseline. RESULTS: Cronbach’s alpha was 0.80 for the three
domains. CFA confirmed the two factor model, with factor loadings ranging from
0.56 to 0.87. Both Tucker-Lewis and Comparative Fit indexes were 0.90, but the
root mean squared error of approximation was 0.08. The highest correlations
were obtained between MLHFQ and SF-12 physical domains (r0.55), and be-
tween the emotional MLHFQ and mental SF-12 domain (r0.53), supporting the
convergent validity. Known-groups validity was shown with significantly worse
scores within patients with readmission (P0.0001). Responsiveness parameters
among improved patients were 1.20 and 1.05 for physical and total score, respec-
tively, indicating large changes, and 0.59 for emotional domain, indicating moder-
ate changes. CONCLUSIONS: The Spanish MLHFQ is valid, reliable and responsive-
ness 6 months after discharge for patients hospitalized with heart failure. Because
its simplicity and ease of application, it may be useful in routine practice and
clinical research. Further, its cross-cultural characteristics make it very useful for
comparisons among countries.
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A UTILITY SINGLE SCORE DERIVED FROM SHORT FORM-36 AND HEALTH
ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH ANTIPHOSPHOLIPID
ANTIBODY SYNDROME: A METHODOLODICAL PROPOSAL
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OBJECTIVES: To propose a single score for quality of life (QoL) derived from the
SF-36 and the HAQ in patients with APS in a tertiary care center. METHODS: It is a
cohort study. Sample was stratified in two groups according to the numbers of
changes in the warfarin dosage over a period of 12 months: Group 1 ( 6 changes in
12 months) and Group 2 ( 6 changes in 12 months). This change was due to INR
oscillation. To assess quality of life, SF-36 and HAQ instruments at baseline and
after 12 months of follow-up were used. To derive the single score, a descriptive
analysis evaluated the variables. Principal component analysis (PCA) was done to
reveal the internal data structure that explains the data variance. APS score was
calculated by the sum of the values obtained by weighting the factor scores for each
component by the proportion of variability explained by the respective component.
To measure APS score consistency to patient’s preference, we based on the hypoth-
esis that Group 2 had a worse quality of life. To test it, we evaluated APS score into
the two time points. To corroborate these results, we applied repeated measures
ANOVA technique. For all statistical tests, the significance level used was  5%.
RESULTS: Group 1: 37 and Group 2: 17 individuals. The descriptive analysis indi-
cates that Group 1 has superior QoL than Group 2. After this step, the minimum and
maximum APS score was obtained: From  2.86905 to  2.797845. Higher score
means the higher the QoL. In order to corroborate our hypothesis, repeated measures
ANOVA results verified that there are significant differences between the two
groups [F (14.27) 24.13, p0.0004]. CONCLUSIONS: APS score is a valid instrument
to measure QoL in APS patients.
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REMINDERS HELP IMPROVING COMPLETION RATE OF HOME-ADMINISTERED
LIFESTYLE QUESTIONNAIRES
Wiederkehr S, Seux M, Faure C, Fournie X
Registrat-Mapi, LYON, France
OBJECTIVES: To administer a questionnaire to 14,000 women in order to measure
various aspects of women’s lifestyle, including sensitive habits, and health.
METHODS: A first population-based mailing was sent to around 31,000 women,
inviting them to complete a questionnaire on a dedicated website or on paper.
Women who did not initially respond were reminded to complete the question-
naire first through an additional mailing and then, for the ones who had still not
responded, through telephone calls. During the second reminder, they were also
offered the possibility to complete the questionnaire over the telephone. Each
reminder was performed after a 3-week waiting period. RESULTS: Among the
30,917 women contacted, 26.0% completed initially the questionnaire. After the
first reminder, the questionnaire was completed by 18.6% of the women who did
not respond to the first mailing and, after the second reminder, by 24.2% of the
women who did not respond after the first reminder. The first mailing followed by
the two reminders resulted in a 52.4% completion rate of the questionnaires. Ques-
tionnaires received after the first mailing, then after the first and second reminder
accounted for respectively 49.6%, 26.9% and 23.4% of the total amount of completed
questionnaires. When offered the possibility to complete the questionnaire on
paper or on a dedicated website, only 18.8% of the women choose the on-line
method. During the telephone call of the second reminder, when offered the pos-
sibility, most women agreed to complete the questionnaire over the telephone
(53.7%). CONCLUSIONS: The methodology employed resulted in an overall good
completion rate (52.4%). The objective of 14,000 completed questionnaires would
have not been achieved without proactive and direct to subject contacts using
reminders, including telephone contacts, allowing finally a two-fold increase of the
initial responders rate.
RESEARCH ON METHODS - Statistical Methods
PRM138
A PROPENSITY TO GET IT RIGHT. A MONTE CARLO SIMULATION STUDY
COMPARING STATISTICAL METHODS TO OBTAIN CORRECT COST-
EFFECTIVENESS ESTIMATES IN OBSERVATIONAL STUDIES
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OBJECTIVES: Estimates of real-world cost-effectiveness are mostly based on obser-
vational data with non-random treatment assignments. Several methods exist to
address the resulting confounding-by-indication, including regression and meth-
ods based on propensity scores (PS). This study examined the performance of these
methods in the context of cost-effectiveness analysis. The PS-methods were: PS
matching (kernel and one-to-one), covariate adjustment using PS, inverse proba-
bility-of-treatment weighting (IPTW) and double robustness, each with several
specifications.METHODS: Thirty-eight adjustment approaches were compared us-
ing Monte Carlo simulations. In each simulation, four differently confounded sam-
ples (n2000) were drawn from a synthesized population. Incremental survival
time and costs were calculated using the results of Weibull survival and general-
ized linear regression. These regressions – with treatment as sole covariate or fully
specified with all confounders - were performed directly or after applying a PS-
method. Each approach was assessed on bias (systematic deviation from the true
effect), accuracy (proportion of simulated results within acceptable distance from
the true values) and reliability (width of bootstrapped confidence intervals) of es-
timates of incremental effects, costs and cost-effectiveness ratios. RESULTS: In
estimates of the average treatment effect in the treated (ATT), kernel and 1-to-1 PS
matching had similar bias and accuracy results, but the reliability of kernel was
better. Regarding average treatment effects for the sample as a whole (ATE), double
robustness and IPTW had the least bias and the best accuracy and reliability. Com-
bining PS methods with fully specified regression models was most likely to lead to
good results. PS covariate adjustment and regression without a PS method scored
worst. CONCLUSIONS: PS methods are preferable to conventional regression for
use in observational cost-effectiveness studies. Combining a PS method with fully
specified regression should be considered for the analysis. Since no method is
always superior, it is advised that sensitivity analyses with different techniques be
performed.
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INCLUDING PATIENTS IN MULTIPLE GROUPS AND MULTIPLE TIMES IN THE
SAME GROUP IN LONGITUDINAL OBSERVATIONAL RESEARCH: A CYSTIC
FIBROSIS EXAMPLE
Pasta DJ, Millar SJ
ICON Late Phase & Outcomes Research, San Francisco, CA, USA
OBJECTIVES: In longitudinal observational studies, patients can meet eligibility
criteria for more than one group and can be eligible multiple times for the same
group. We used Epidemiologic Study of Cystic Fibrosis data to explore different
inclusion decisions when evaluating dornase alfa treatment. METHODS: The dor-
nase alfa group included patients enrolled 2 years before starting consistent dor-
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